Connor, Clark & Lunn Investment Management (CC&L)’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.9M | Buy |
|
|||||
|
2025
Q1 | $9.51M | Sell |
|
|||||
|
2024
Q4 | $12.6M | Sell |
|
|||||
|
2024
Q3 | $15M | Sell |
|
|||||
|
2024
Q2 | $20.4M | Buy |
|
|||||
|
2024
Q1 | $15.8M | Buy |
|
|||||
|
2023
Q4 | $19.6M | Sell |
|
|||||
|
2023
Q3 | $13.2M | Buy |
|
|||||
|
2023
Q2 | $12.8M | Buy |
|
|||||
|
2023
Q1 | $9.38M | Buy |
|
|||||
|
2022
Q4 | $7.79M | Sell |
|
|||||
|
2022
Q3 | $8.34M | Buy |
|
|||||
|
2022
Q2 | $2.13M | Buy |
|
|||||
|
2022
Q1 | $1.4M | Buy |
|
|||||
|
2018
Q3 | – | Sell |
|
|||||
|
2018
Q2 | $1.72M | Buy |
|
|||||
|
2015
Q1 | – | Sell |
|
|||||
|
2014
Q4 | $330K | Buy |
|
|||||
|
2013
Q3 | – | Sell |
|
|||||
|
2013
Q2 | $258K | Buy |
|